Home/Pipeline/QuickProfile Cardiac Markers

QuickProfile Cardiac Markers

Myocardial Infarction

CommercialActive

Key Facts

Indication

Myocardial Infarction

Phase

Commercial

Status

Active

Company

LumiQuick Diagnostics

About LumiQuick Diagnostics

LumiQuick Diagnostics is a commercial-stage, private diagnostics company offering a diverse portfolio of rapid lateral flow tests and ELISA kits. Its product lines target human health (infectious diseases, cardiac markers, fertility, drugs of abuse), veterinary/food safety, and environmental/biothreat detection, leveraging a core immunochromatography technology platform. The company has achieved commercial traction, notably with an FDA EUA for its Boson Rapid SARS-CoV-2 Antigen Home Test, and operates in a competitive but expansive global rapid diagnostics market. Its strategy involves broadening its test menu and leveraging its QuickProfile and EnviroSafe brands across multiple sectors.

View full company profile

Therapeutic Areas

Infectious Disease Cardiology Oncology Women's Health Toxicology Veterinary Health

Other Myocardial Infarction Drugs

Drug	Company	Phase	Status
KEAP1/NRF2 Program	Grove Biopharma	Pre-clinical	Active
VANADIS® BMOV	CFM Pharma	Phase 1	Active
Lead Peptide Program	ResoTher Pharma	Phase 2a	Active
Myocardial Infarction Cardiac Patch	Matricelf	Preclinical	Active